Hospira, Inc. has completed the acquisition of Mayne Pharma Ltd. in a transaction valued at $2.1 billion. Mayne Pharma, an Australia-based specialty injectable pharmaceuticals company, significantly expands Hospira’s global operations and doubles its international sales. The acquisition is expected to expand Hospira’s oncology presence, provide potent/cytotoxic manufacturing and R&D capabilities, and help reduce the overall costs of healthcare by increasing the number of specialt...